- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Michael Thompson on Conducting Precision Medicine Trials in the Community Setting
Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare, discusses challenges associated with conducting precision medicine trials in the community setting.
Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare, discusses challenges associated with conducting precision medicine trials in the community setting.
Transcript
What challenges are associated with conducting precision medicine trials in the community setting?
So, with precision medicine, you need to have tissue, and if you need new tissue, that is sometimes a barrier based on location or cost and toxicity of getting the new tissue. There is a barrier of getting the testing done, whether that’s on a research study or before the research program actually and the eligibility criteria, which may limit patient accrual. For many of these patients that have been through multiple lines of therapy and there aren’t a lot of great options, anything that slows things down can cause them to go from relatively healthy and able to go on a trial, to unhealthy and unable to go on the trial, or even dying. So, this has been seen, and we have to do things efficiently and fast in order to overcome these accrual barriers.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
